Journal of Clinical Densitometry
Volume 13, Issue 4 , Pages 335-345 , October 2010

Risk Communication and Shared Decision Making in the Care of Patients With Osteoporosis

  • E. Michael Lewiecki

      Affiliations

    • Corresponding Author InformationAddress correspondence to: E. Michael Lewiecki, MD, FACP, FACE, New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM 87106.

Received 26 April 2010 ,Revised 23 June 2010 ,Accepted 23 June 2010.

References 

  1. Epictetus. 2010 Epictetus. BrainyQuote.com, Xplore Inc, 2010. Available at: http://www.brainyquote.com/quotes/quotes/e/epictetus149127.htmlAccessed: April 4, 2010
  2. Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785–795
  3. Baim S, Binkley N, Bilezikian JP, et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom. 2008;11(1):75–91
  4. World Health Organization . 2009 FRAX WHO fracture risk assessment tool. Available at: http://www.shef.ac.uk/FRAX/Accessed: November 1, 2009
  5. National Osteoporosis Foundation . Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008;
  6. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19(4):399–428
  7. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148(3):197–213
  8. Chesnut CH. Osteoporosis, an underdiagnosed disease. JAMA. 2001;286(22):2865–2866
  9. Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int. 2004;15(2):120–124
  10. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023–1031
  11. Eastell R, Garnero P, Vrijens L, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int. 2003;72:408;[abstract P297]
  12. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003;14(12):965–968
  13. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013–1022
  14. McCombs JS, Thiebaud P, Laughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48(3):271–287
  15. Wilkes MM, Navickis RJ, Chan WW, Lewiecki EM. Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int. 2010;21(4):679–688
  16. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115(3):209–216
  17. Silverman SL, Greenwald M, Klein RA, Drinkwater BL. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol. 1997;89:321–325
  18. Winzenberg T, Oldenburg B, Frendin S, et al. The effect on behavior and bone mineral density of individualized bone mineral density feedback and educational interventions in premenopausal women: a randomized controlled trial [NCT00273260]. BMC Public Health. 2006;6:1–12
  19. Wilson SR, Strub P, Buist AS, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010;181(6):566–577
  20. Weymiller AJ, Montori VM, Jones LA, et al. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med. 2007;167(10):1076–1082
  21. Lewiecki EM, Watts NB. Assessing response to osteoporosis therapy. Osteoporos Int. 2008;19(10):1363–1368
  22. Watts NB, Ettinger B, LeBoff MS. FRAX facts. J Bone Miner Res. 2009;24(6):975–979
  23. Covello VT. Risk and crisis communication. Center for Risk Communication. Available at: www.centre4riskman.com/downloads/rc_slides_2002.ppt2002;Accessed: April 10, 2010
  24. Sandman PM. Crisis communication (high hazard, high outrage). The Peter Sandman Risk Communication Website. Available at: http://www.psandman.com/index-CC.htm2010;Accessed: April 10, 2010
  25. Covello VT, Sandman PM. Risk communication: evolution and revolution. The Peter Sandman Risk Communication Website. Available at: http://www.psandman.com/articles/covello.htm2001;Accessed: April 10, 2010
  26. Radonich M. Communicating radiation risk to the public. Community Environmental Monitoring Program 25th Anniversary Annual Workshop. Available at: http://www.cemp.dri.edu/cemp/workshop2006/presentations/Radonich-Communicating_Radiation_Risk_to_the_Public-Part_1.pdf2006;Accessed: April 10, 2010
  27. Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients. Osteoporos Int. 2000;11(6):533–536
  28. Lewiecki EM, Binkley N. Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis. Endocr Pract. 2009;24(10):1643–1646
  29. Giangregorio L, Dolovich L, Cranney A, et al. Osteoporosis risk perceptions among patients who have sustained a fragility fracture. Patient Educ Couns. 2009;74(2):213–220
  30. Solomon DH, Finkelstein JS, Katz JN, et al. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med. 2003;115(5):398–400
  31. Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002;162(19):2217–2222
  32. Kamel HK, Hussain MS, Tariq S, et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med. 2000;109(4):326–328
  33. Torgerson DJ, Dolan P. Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis. 1998;57(6):378–379
  34. Giangregorio L, Papaioannou A, Cranney A, et al. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum. 2006;35(5):293–305
  35. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006;119(4 Suppl 1):S12–S17
  36. Edwards A, Elwyn G. How should effectiveness of risk communication to aid patients' decisions be judged? A review of the literature. Med Decis Making. 1999;19(4):428–434
  37. Rothman AJ, Kiviniemi MT. Treating people with information: an analysis and review of approaches to communicating health risk information. J Natl Cancer Inst Monogr. 1999;(25):44–51
  38. Waitzkin H. Doctor-patient communication. Clinical implications of social scientific research. JAMA. 1984;252(17):2441–2446
  39. Braddock CH, Edwards KA, Hasenberg NM, et al. Informed decision making in outpatient practice: time to get back to basics. JAMA. 1999;282(24):2313–2320
  40. Whitney SN. A new model of medical decisions: exploring the limits of shared decision making. Med Decis Making. 2003;23(4):275–280
  41. Lloyd AJ, Hayes PD, London NJ, et al. Patients' ability to recall risk associated with treatment options. Lancet. 1999;353(9153):645;[research letter]
  42. O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2009;(3):CD001431
  43. Meyer G, Steckelberg A, Muhlhauser I. Analysis of consumer information brochures on osteoporosis prevention and treatment. Ger Med Sci. 2007;5:1–9
  44. Lewiecki EM, Rudolph LA, Kiebzak GM, et al. Assessment of osteoporosis-website quality. Osteoporos Int. 2006;17(5):741–752
  45. Hollon MF, Larson EB, Koepsell TD, Downer AE. Direct-to-consumer marketing of osteoporosis drugs and bone densitometry. Ann Pharmacother. 2003;37(7–8):976–981
  46. Chao BA. Evaluating the educational content of direct-to-consumer fulfillment materials. Am J Health Syst Pharm. 2005;62(6):620–625
  47. Ancker JS, Senathirajah Y, Kukafka R, Starren JB. Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc. 2006;13(6):608–618
  48. Schapira MM, Nattinger AB, McHorney CA. Frequency or probability? A qualitative study of risk communication formats used in health care. Med Decis Making. 2001;21(6):459–467
  49. Royak-Schaler R, Blocker DE, Yali AM, et al. Breast and colorectal cancer risk communication approaches with low-income African-American and Hispanic women: implications for healthcare providers. J Natl Med Assoc. 2004;96(5):598–608
  50. Schwartz LM, Woloshin S, Black WC, Welch HG. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med. 1997;127(11):966–972
  51. Lipkus IM, Samsa G, Rimer BK. General performance on a numeracy scale among highly educated samples. Med Decis Making. 2001;21(1):37–44
  52. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(1):89–90
  53. Siris ES, Oster MW, Bilezikian JP. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(17):1791;[letter]
  54. Hofbauer LC, Miehlke S. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(17):1790;[letter]
  55. Shaheen NJ. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(17):1790–1791[letter]
  56. Robins HI, Holen KD. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(17):1790;[letter]
  57. Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(17):1789–1790[letter]
  58. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(17):1789;[letter]
  59. Furedi A. The public health implications of the 1995 ‘pill scare’. Hum Reprod Update. 1999;5(6):621–626
  60. Galesic M, Garcia-Retamero R, Gigerenzer G. Using icon arrays to communicate medical risks: overcoming low numeracy. Health Psychol. 2009;28(2):210–216
  61. Gaissmaier W, Gigerenzer G. Statistical illiteracy undermines informed shared decision making. Z Evid Fortbild Qual Gesundhwes. 2008;102(7):411–413
  62. Charles C, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med. 1999;49(5):651–661
  63. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44(5):681–692
  64. Woolf SH, Chan EC, Harris R, et al. Promoting informed choice: transforming health care to dispense knowledge for decision making. Ann Intern Med. 2005;143(4):293–300
  65. Ford S, Schofield T, Hope T. What are the ingredients for a successful evidence-based patient choice consultation? a qualitative study. Soc Sci Med. 2003;56(3):589–602
  66. Epstein RM, Alper BS, Quill TE. Communicating evidence for participatory decision making. JAMA. 2004;291(19):2359–2366
  67. Robinson A, Thomson R. Variability in patient preferences for participating in medical decision making: implication for the use of decision support tools. Qual Health Care. 2001;10(Suppl 1):i34–i38
  68. McNutt RA. Shared medical decision making: problems, process, progress. JAMA. 2004;292(20):2516–2518
  69. O'Connor AM. A call to standardize measures for judging the efficacy of interventions to aid patients' decision making. Med Decis Making. 1999;19(4):504–505
  70. Edwards A, Unigwe S, Elwyn G, Hood K. Effects of communicating individual risks in screening programmes: Cochrane systematic review. BMJ. 2003;327(7417):703–709
  71. Lipkus IM, Hollands JG. The visual communication of risk. J Natl Cancer Inst Monogr. 1999;(25):149–163
  72. Mandelblatt J, Kreling B, Figeuriedo M, Feng S. What is the impact of shared decision making on treatment and outcomes for older women with breast cancer?. J Clin Oncol. 2006;24(30):4908–4913
  73. Pencille LJ, Campbell ME, Van Houten HK, et al. Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practice. Trials. 2009;10:1–9
  74. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(3):1117–1123
  75. Briot K, Ravaud P, Dargent-Molina P, et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int. 2009;20(4):625–630
  76. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int. 2007;18(6):711–719
  77. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254–1259
  78. Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX((R)). Bone. 2009;44:1049–1054
  79. McCloskey EV, Johansson H, Oden A, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int. 2009;20(5):811–817
  80. Baim S, Wilson CR, Lewiecki EM, et al. Precision assessment and radiation safety for dual-energy x-ray absorptiometry: position paper of the international society for clinical densitometry. J Clin Densitom. 2005;8(4):371–378
  81. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–1489
  82. Harvard Center for Risk Analysis . Causes of death. Harvard School of Public Health; 2009;Available at: http://www.hcra.harvard.edu/quiz.htmlAccessed: February 19, 2010
  83. Cohen JT, Neumann PJ. What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits). Health Aff (Millwood). 2007;26(3):636–646
  84. Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001;12(5):417–427

PII: S1094-6950(10)00202-7

doi: 10.1016/j.jocd.2010.06.005

Journal of Clinical Densitometry
Volume 13, Issue 4 , Pages 335-345 , October 2010

Article Tools

* Image Usage & Resolution